[1]赵璐 庞蒙蒙 宋庆桥 吴华芹.CT血流储备分数联合斑块分析在冠心病中的研究进展[J].心血管病学进展,2025,(1):20.[doi:10.16806/j.cnki.issn.1004-3934.2025.01.005]
　ZHAO Lu,PANG Mengmeng,SONG Qingqiao,et al.CT Fractional Flow Reserve Combined with Plaque Analysis in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2025,(1):20.[doi:10.16806/j.cnki.issn.1004-3934.2025.01.005]
点击复制

CT血流储备分数联合斑块分析在冠心病中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年1期
页码:
20
栏目:
综述
出版日期:
2025-01-25

文章信息/Info

Title:
CT Fractional Flow Reserve Combined with Plaque Analysis in Coronary Heart Disease
作者:
赵璐 庞蒙蒙 宋庆桥 吴华芹
(中国中医科学院广安门医院,北京,100053)
Author(s):
ZHAO Lu; PANG Mengmeng; SONG Qingqiao; WU Huaqin
(Guang ’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China)
关键词:
冠状动脉粥样硬化性心脏病; CT血流储备分数; 斑块特征
Keywords:
Coronary atherosclerotic heart disease;  CT fractional flow reserve;  Plaque characteristics
DOI:
10.16806/j.cnki.issn.1004-3934.2025.01.005
摘要:
随着冠状动脉粥样硬化性心脏病（CHD）发病率和死亡率的提升，对于CHD的无创和有创诊疗方式不断改进。近年来，CT血流储备分数（FFRCT）在血流动力学及心肌缺血功能领域逐渐受到关注，同时由于斑块特征与缺血密切相关，采用冠状动脉计算机断层血管造影进行斑块分析已广泛应用于临床。现总结基于FFRCT联合斑块分析在CHD中的研究进展，探讨FFRCT联合斑块分析在冠状动脉评估中的优势及不足，以期为CHD的诊断、治疗提供思路和方法。
Abstract:
With the increasing incidence and mortality of coronary atherosclerotic heart disease (CHD), the non-invasive and invasive diagnosis and treatment methods for CHD have been continuously improved. In recent years, CT fractional flow reserve (FFRCT) has gradually attracted attention in the field of hemodynamics and myocardial ischemic function. At the same time, because plaque characteristics are closely related to ischemia, coronary CT angiography for plaque analysis has been widely used in clinical practice. This article summarizes the research progress of FFRCT combined with plaque analysis in CHD, and discusses the advantages and disadvantages of FFR CT combined with plaque analysis in coronary artery assessment, in order to provide ideas and methods for the diagnosis and treatment of CHD.

参考文献/References:

[1] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2022概要[J]. 心脑血管病防治,2023,23(7):1-19,24.

[2] Min JK,Taylor CA,Achenbach S,et al. Noninvasive fractional flow reserve derived from coronary ct angiography:clinical data and scientific principles[J]. JACC Cardiovasc Imaging,2015,8(10):1209-1222.

[3] De Bruyne B,Pijls NH,Kalesan B,et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease[J]. N Engl J Med,2012,367(11):991-1001.

[4] Shantouf RS,Mehra A. Coronary fractional flow reserve[J]. AJR Am J Roentgenol,2015,204(3):W261-W265.

[5] Pijls NH,van Son JA,Kirkeeide RL,et al. Experimental basis of determining maximum coronary, myocardial,and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty[J]. Circulation,1993,87(4):1354-1367.

[6] Fihn SD,Gardin JM,Abrams J,et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines,and the American College of Physicians,American Association for Thoracic Surgery,Preventive Cardiovascular Nurses Association,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons[J]. Circulation,2012,126(25):e354-e471.

[7] Task Force Members,Montalescot G,Sechtem U,et al. 2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J,2013,34(38):2949-3003.

[8] 孙欣杰. 基于CCTA的冠脉斑块特征参数与血流储备分数的相关性研究[D]. 南京:南京医科大学,2021.

[9] Gaur S,?vrehus KA,Dey D,et al. Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions[J]. Eur Heart J,2016,37(15):1220-1227.

[10] Tang LM,Liu F,Dong TY,et al. Synergistic value of fractional flow reserve and low?density non?calcified plaque based on coronary computed tomography angiography for the identification of lesion?specific ischemia[J]. Exp Ther Med,2022,24(5):701.

[11] Yan H,Zhao N,Geng W,et al. Pericoronary fat attenuation index and coronary plaque quantified from coronary computed tomography angiography identify ischemia-causing lesions[J]. Int J Cardiol,2022,357:8-13.

[12] 丁楠. 基于CCTA的FFRct及斑块分析对冠脉缺血的诊断价值[D]. 郑州:郑州大学,2021.

[13] 朱占英,陈兴灿,徐佳妮,等. 无创血流储备分数联合CCTA的斑块特征对冠心病诊断价值[J]. 浙江临床医学,2024,26(4):506-508.

[14] 杨露露,徐金娥,刘冲. 冠状动脉无创血流储备分数诊断冠心病效能的研究进展[J]. 影像技术,2023,35(2):70-75.

[15] 宋瑶,霍怀璧,李晗,等. 冠状动脉CTA多参数AI特征对急性冠脉综合征的诊断价值[J]. 放射学实践,2023,38(7):873-878.

[16] Yang S,Choi G,Zhang J,et al. Association among local hemodynamic parameters derived from ct angiography and their comparable implications in development of acute coronary syndrome[J]. Front Cardiovasc Med,2021,8:713835.

[17] Wang J,Chen HW,Zhou LJ,et al. Prediction of acute myocardial infarction by multi-parameter coronary computed tomography angiography[J]. Clin Radiol,2022,77(6):458-465.

[18] Yang L,Xu PP,Schoepf UJ,et al. Serial coronary CT angiography-derived fractional flow reserve and plaque progression can predict long-term outcomes of coronary artery disease[J]. Eur Radiol,2021,31(9):7110-7120.

[19] 王勇,武汉忠,常燕翔,等. 冠心病患者主要不良心脏事件的相关因素及CTA相关参数的诊断价值研究[J]. 中国CT和MRI杂志,2023,21(8):82-64.

[20] 夏连仁. FFRCT、MPI和斑块特征对冠心病患者主要不良心脏事件的预测价值分析[J]. 实用中西医结合临床,2023,23(10):85-87,120.

[21] 薛秋苍,徐怡,孙欣杰,等. FFRCT联合斑块特征与心肌灌注显像对冠心病患者主要不良心脏事件预测效能的比较[J]. 南京医科大学学报(自然科学版),2021,41(5):757-762.

[22] 孙欣杰,徐怡,朱晓梅,等. 基于冠状动脉CTA的FFRCT与斑块特征对冠心病患者主要不良心脏事件的预测价值[J]. 中国医学计算机成像杂志,2021,27(4):296-301.

[23] Wang J,Zhou L,Chen H,et al. Predicting major adverse cardiac events based on multi-parameter coronary computed tomography angiography[J]. Med Phys,2022,49(6):3612-3623.

相似文献/References:

[1]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
　ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[2]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
　CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[3]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
　SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[4]孙涛 左权 周辉 刘安康 梁诚 汤圣兴.末梢桡动脉和无鞘技术在冠状动脉介入治疗中的应用现状[J].心血管病学进展,2020,(5):456.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.005]
[5]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
　XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(1):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
[6]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
　XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(1):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[7]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
　SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(1):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[8]李英  刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
　LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(1):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[9]肖亚楠 高传玉.经皮冠脉介入术后短程双联抗血小板治疗的研究进展[J].心血管病学进展,2021,(4):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
　XIAO Yanan,GAO Chuanyu.Short-term Dual Antiplatelet Therapy after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2021,(1):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
[10]吉蓉 寿锡凌.秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J].心血管病学进展,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
　JI Rong,SHOU Xiling.Research Progress and Controversy of Colchicine in Prevention and Treatment of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]

更新日期/Last Update: 2025-02-26